Charles A. Schiffer
Schiffer, Charles A.
VIAF ID: 85581179 (Personal)
Permalink: http://viaf.org/viaf/85581179
Preferred Forms
- 100 0 _ ‡a Charles A. Schiffer
-
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States | |
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. | |
The evolution of dasatinib dosage over the years and its relevance to other anticancer medications | |
Gemtuzumab ozogamicin: time to resurrect? | |
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | |
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs | |
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study | |
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. | |
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study | |
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | |
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. | |
Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129 |